Zhihong (Hana) Yun, BSc - De Perrot Research Lab

Marc de Perrot

Reperfusion strategies while on ECMO for catastrophic PE: Keep fishing or cut bait? February 25, 2026
No abstract
Identifying patients with high risk stage I NSCLC using tumor-informed plasma ctDNA February 23, 2026
Circulating tumor DNA (ctDNA) has emerged as an important prognostic factor in cancer patients. Management of early stage non-small cell lung cancer (NSCLC) remains challenging with a high rate of disease recurrence. In this prospective cohort, 153 patients with clinical stage I NSCLC (75.8% pathologic stage I) underwent real-time plasma ctDNA testing using a tumor-informed […]
Utility of Computed Tomography-Based Intraoperative Surgical Margin Evaluation in Wedge-Resected Lung Specimens February 9, 2026
CONCLUSIONS: CT-based margin evaluation method can provide an intraoperative timely and more reliable estimate of the pathMargin compared to surgeon's estimates and could be a novel approach to ensure more sufficient surgical margins during wedge resection.
Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies February 4, 2026
Neoadjuvant chemoimmunotherapy (chemo-IO) has fundamentally reshaped the treatment paradigm for resectable non-small cell lung cancer (NSCLC), challenging long-held surgical boundaries and redefining what constitutes "resectable" disease. Trials such as CheckMate-816, KEYNOTE-671, and AEGEAN have demonstrated that integrating immune checkpoint blockade with chemotherapy yields unprecedented rates of pathological response and event-free survival, positioning chemo-IO as the […]
Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement January 18, 2026
No abstract
Clinical implications of frailty in hospitalized patients with pulmonary arterial hypertension December 24, 2025
ObjectivesFrailty is associated with increased morbidity and mortality in chronic lung disease, but its prognosis has not been evaluated in pulmonary arterial hypertension (PAH). This study aimed to assess: (1) impact of frailty on hospital length of stay (LOS) and health-care utilization in PAH; (2) association of frailty with 1-year post-discharge outcomes.MethodsRetrospective, single-centered cohort study […]
Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement December 16, 2025
Clinical trials in lung transplantation have been hindered by a lack of clarity on the formulation and significance of endpoints for evaluating therapeutic efficacy. To address this challenge, a multidisciplinary working group from the International Society for Heart and Lung Transplantation developed consensus recommendations on endpoints beyond mortality. These endpoints include primary graft dysfunction (PGD), […]
Reply to the Letter to the Editor: Rethinking the clinical utility of machine learning for CTEPH severity November 28, 2025
No abstract
Endothelin-1 overexpression in pulmonary endarterectomy specimens of CTEPH patients is associated with pulmonary hypertension development September 27, 2025
CONCLUSIONS: ET-1 release from thromboembolic material of CTEPH patients could be an important mechanism leading to PH. Hence, ET-1 receptor antagonists should continue to be investigated as a potential therapeutic agent in CTEPH patients.
The Tempest Surrounding Lung Transplant for Lung Cancer, With Lung Cancer, or With Isolated Lung Metastases September 12, 2025
Lung transplantation for cancer is controversial. The hesitancy has largely been driven by historical outcomes. However, early-stage lung cancer does not significantly affect the outcome of lung transplant for other end-stage lung diseases. We have also made more donor lungs available and hence can consider transplanting patients where the only curative option is to resect […]
One thousand cases of ex vivo lung perfusion for lung transplantation: A single-center experience September 5, 2025
CONCLUSIONS: Ex vivo lung perfusion has emerged as a safe, effective, and scalable platform for donor lung evaluation. Its integration into clinical practice has supported broader donor organ use and excellent patient outcomes, while laying the foundation for continued innovation in lung transplantation.
Utility of machine learning for predicting severe chronic thromboembolic pulmonary hypertension based on CT metrics in a surgical cohort August 23, 2025
CONCLUSIONS: While measures of PE burden had little bearing on PH severity independently, the RV/LV ratio, extent of disease in various segments, total webs observed, and patient demographics improved performance of machine learning models in identifying severe PH.
Management of chronic thromboembolic pulmonary hypertension July 13, 2025
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe and progressive disease. Three treatment modalities are available: pulmonary endarterectomy, balloon pulmonary angioplasty, and pulmonary hypertension (PH) medical therapy. Both mechanical therapies may also be considered in patients with chronic thromboembolic pulmonary disease without PH. Patients should be referred to expert centers, as full surgical evaluation is […]
Ex vivo lung perfusion of pediatric lungs July 11, 2025
No abstract
Intraoperative Surgical Margin Assessment of Sublobar Lung Resection Specimens Using Computed Tomography June 25, 2025
CONCLUSIONS: SM measurement by CT is feasible and has the potential to aid in the evaluation of SM intraoperatively. However, surgeons must anticipate the potentially greater discordance when using this technique for subsolid tumors.

Partners: Latner Labs

University of Toronto

University Health Network